Does the low mood linked to Wegovy go away over time?

Is the low mood people report on Wegovy a recognised side effect?

Yes, mood changes appear in the safety data, though the picture is more nuanced than a simple yes or no. The NHS medicines information for semaglutide lists low mood, mood changes and, in rarer cases, thoughts of self-harm as side effects to be aware of. These are not listed as common (affecting more than one person in ten) but they are listed — which means they have been reported with enough consistency to warrant inclusion in the product's safety profile.

The STEP 1 phase 3 trial, which compared semaglutide 2.4mg against placebo over 68 weeks in adults with obesity, did not find a statistically significant difference in depression rates between the two groups. That is reassuring, and it is the most rigorous evidence we have. Clinical trials are not perfect mirrors of everyday experience, however. They exclude people with active psychiatric conditions, and they measure outcomes at set intervals rather than capturing the week-by-week texture of how someone feels. So a real patient's experience can look different from a trial summary.

Some people describe an emotional flatness rather than textbook depression: reduced motivation, a muted response to things that normally bring pleasure, a sense of distance. This may partly reflect appetite suppression itself. Food has neurochemical rewards attached to it, and removing much of that drive can feel strange for a while. In most cases this settles within the first few weeks of a given dose.

Does the mood change go away as treatment continues?

For most people, yes. The pattern seen most often is that emotional side effects, where they occur, are most noticeable after starting treatment or after a dose increase, then ease as the body adjusts. This mirrors the trajectory of gastrointestinal side effects, nausea tends to be worst in the first week or two of a new dose, then typically fades. Mood tends to follow a similar arc, though the timeline is less predictable than nausea.

The practical implication is that mood changes appearing in the first couple of weeks of a new dose are worth noting but not immediately alarming if they are mild and improving. Mood changes that arrive later, worsen over time, or feel qualitatively different from ordinary tiredness or stress deserve more urgent attention. If you are three or four months into a stable dose and low mood is getting worse rather than better, that is not an adjustment effect, it needs clinical review.

There is also a weight-loss effect to factor in. Losing a significant amount of weight changes your body's hormonal environment, your relationship with food, and sometimes your sense of identity. Those changes can be emotionally complex, and not everyone processes them smoothly. This is one reason semaglutide's relationship with mental health cuts in more than one direction: some people report a genuine lift in mood as their weight falls and their confidence builds. Others find the process harder emotionally than they expected. Both are valid, and a good prescribing service will want to know which applies to you.

When should you contact your prescriber rather than waiting it out?

The clearest answer is: sooner than you think. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines explicitly names suicidal ideation and self-harm thoughts as side effects to report promptly to a healthcare professional. This is not a cause for panic, but it is a clear instruction not to wait for your next scheduled review if your mood has shifted into that territory.

Even short of those extremes, the right threshold for contacting your prescriber is lower than most patients set for themselves. If low mood is affecting your sleep, your relationships, your ability to work, or your enjoyment of daily life for more than a few days at a consistent dose, that is worth a conversation. A clinician can assess whether a dose reduction, a pause in titration, or additional support is appropriate, low mood linked to Wegovy does not automatically mean stopping treatment; it means adjusting it thoughtfully.

You can report suspected side effects directly through the MHRA's Yellow Card scheme. Doing so helps regulators build a more complete picture of how these medicines behave in the real world, beyond the controlled conditions of a clinical trial. It takes a few minutes and it genuinely matters.

If you are thinking about starting Wegovy and want to understand more about the cost side of treatment, the Wegovy pricing page covers what private prescriptions typically include. For broader questions about how semaglutide works and who it is suitable for, our semaglutide overview is a good starting point.

What does this mean if you are already on Wegovy or thinking about starting?

If you are already on Wegovy and have noticed low mood, the most important step is to tell someone who can act on it, your prescriber, your GP, or a mental health professional if the symptoms are significant. Do not adjust your dose yourself. Stopping or reducing semaglutide without clinical guidance can cause unnecessary disruption to your treatment and does not remove the risk of a rebound in mood symptoms.

If you are considering starting Wegovy and have a history of depression or other mood conditions, that history should be part of your consultation. It does not automatically disqualify you from treatment, but it does mean your prescriber needs the full picture to make the right call. Our in-depth look at whether Wegovy can cause depression goes further into the mechanism and the evidence, and is worth reading before your consultation if this is a concern for you.

Wegovy is assessed and prescribed on an individual basis after a full clinical review. If you are ready to talk to a prescriber about whether it is right for you, check your eligibility through a free consultation with our clinical team.